U.S. Rare Earth Minerals is Other Metals, Minerals and Mining in United States that focus on drug candidate business. Founded in 2008. They cover business area such as Bioxytran Inc, anti-necrosis drug, medical condition, Ischemia, commercialization, treatment, catastrophic brain damage, hypoxic condition, brain stroke, its product candidate, oxygen, tissue, blood, wound healing application.
Other Metals, Minerals and Mining
2008
( 16 years old in 2024 )
Drug Candidate
-
78-365 Highway 111
Suite 287
La Quinta, CA 92253
United States
Private
Bioxytran Incanti-necrosis drugmedical conditionIschemiacommercializationtreatmentcatastrophic brain damagehypoxic conditionbrain strokeits product candidateoxygentissuebloodwound healing application
* We use standard office opening hours in near U.S. Rare Earth Minerals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
U.S. Rare Earth Minerals is Other Metals, Minerals and Mining business from United States that founded in 2008 (16 years old in 2024), U.S. Rare Earth Minerals business is focusing on Drug Candidate.
U.S. Rare Earth Minerals headquarter office and corporate office address is located in 78-365 Highway 111 Suite 287 La Quinta, CA 92253 United States.
U.S. Rare Earth Minerals was founded in United States.
In 2024, U.S. Rare Earth Minerals is currently focus on drug candidate sector.
Above is snippet of Google Trends for "drug candidate" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with U.S. Rare Earth Minerals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
